2024年营业收入和利润总额累计降幅快速收窄 2024年农药行业营收和利润总额累计降幅快速收窄，行业效益表现出筑底回升态势。5月15日，在"2024 年度农药行业销售额5亿元以上企业名单"发布会上，中国农药工业协会副会长兼秘书长李钟华给出上述 判断。 中国农药工业协会在宁夏银川召开的上述发布会上给出的统计数据显示，2024年度农药行业销售额5亿 元以上企业115家，总销售额达到2848.87亿元；10亿元以上企业81家，较上年增加8家；50亿元以上企 业13家，较上年增加1家；其中4家企业销售额超过百亿元，行业集中度持续提升。 李钟华介绍说，2024年农药行业积极应对风险挑战，坚持稳中求进、以进促稳的基调，行业效益呈现筑 底回升态势。 国家统计局数据显示，2024年农药行业规模以上企业883家，创历史新高；规模以上企业累计营业收入 较上年增长3.2%，利润总额较上年下降3.4%，行业利润率5.7%，处于历史低位。两大板块中，化学农 药制造业营业收入较上年增长3.5%，利润总额较上年下降6.9%；生物化学农药及微生物农药制造业营 业收入较上年增长0.1%，利润总额较上年增长40.6%。从全年走势看，行业效益呈现 ...

Summary of Glyphosate Industry Update Industry Overview - The glyphosate industry is currently facing significant challenges, particularly for Bayer, which is dealing with a substantial number of lawsuits related to glyphosate's carcinogenic claims. Bayer has paid over $10 billion in settlements but still has approximately 60,000 lawsuits pending, with recent single compensation amounts reaching historical highs, intensifying financial pressure [1][2][4]. Key Points Bayer's Financial Struggles - Bayer's net profit is projected to decline by 46% in 2024, with its stock price hitting the lowest point since 2004, resulting in a market capitalization loss of $24 billion [1][2]. - The company has set aside $5.9 billion for litigation-related liabilities, but recent high judgments exceed its net profit, posing a severe threat to financial stability [2]. Potential Bankruptcy of Monsanto - Bayer is considering the bankruptcy of its subsidiary Monsanto to isolate litigation liabilities, although this strategy is controversial within the U.S. legal framework and is under scrutiny from global regulatory bodies [4][6]. - The Canadian Supreme Court has approved a class action lawsuit against Monsanto for up to CAD 1.2 billion, adding to the uncertainty surrounding the company [1][4]. Market Impact - The glyphosate segment has seen a 4% decline in sales, with profit expectations adjusted down to €10 billion due to the ongoing litigation and market confidence issues [5]. - If Monsanto ceases operations, it could lead to a search for alternative products in the U.S. market, potentially driving up prices for glyphosate and its substitutes, although no fully effective and cost-competitive alternatives currently exist [3][11]. Price Dynamics and Inventory Issues - Glyphosate prices are under pressure due to multiple factors, including the global economic crisis, the COVID-19 pandemic, the Russia-Ukraine conflict, and changes in tariff policies. Current overseas inventory levels indicate that 20%-25% still need to be processed [10][11]. - The market price for glyphosate has dropped significantly, influenced by these external factors, and is currently around 20,000 RMB, down from a peak of 80,000 RMB [11][14]. Production Capacity and Regional Demand - Monsanto's current production capacity is 370,000 tons, with an actual output of approximately 280,000 tons, primarily serving the South American market, especially Brazil [8]. - In China, glyphosate production capacities vary among companies, with significant players like Xingfa Group and Jiangshan Co. having capacities of 250,000 tons and 80,000 tons, respectively [9][21]. Future Industry Outlook - The glyphosate industry is under restructuring pressure, with potential bankruptcies looming, but the exact outcomes remain uncertain. The situation is expected to evolve until at least the second half of 2027 [13]. - The public perception of glyphosate's safety is critical, as any confirmation of its carcinogenic risks could lead to widespread industry reevaluation and potential product withdrawals [7][12]. Alternative Products - Alternatives to glyphosate, such as glufosinate, are available but are generally more expensive, limiting their market penetration. The effectiveness of these alternatives varies, and the long-term use of glyphosate has led to increased weed resistance, complicating the sustainability of its use [16][20]. Conclusion - The glyphosate industry is at a critical juncture, with Bayer's financial health and Monsanto's future hanging in the balance. The ongoing litigation, market pressures, and potential shifts in consumer preferences will shape the industry's landscape in the coming years.

Investment Rating - The report indicates a positive outlook for the chemical industry, with a recommendation for a defensive investment strategy due to ongoing market uncertainties [2][25]. Core Insights - The chemical market has seen an increase due to unexpected tariff reductions, with the Shenwan Chemical Index rising by 1.82%, outperforming the CSI 300 Index by 0.7% [2][10]. - The report highlights strong performance in military and robotics sectors, as well as stocks benefiting from tariff reductions [2]. - The easing of tariffs between China and the US, with a cancellation of 91% of additional tariffs, is expected to lead to a recovery in previously depressed export chains [2][3]. - Oil prices are projected to stabilize within a range, influenced by geopolitical factors and demand dynamics [2]. - The AI sector is showing significant growth, with major companies reporting substantial contributions from AI capabilities [2]. Summary by Sections Market Review - The Brent crude oil futures average price was $65.52 per barrel, up 5.6% from the previous week, while WTI futures averaged $62.58 per barrel, an increase of 5.98% [10]. - The basic chemical sector outperformed the index, while the petrochemical sector underperformed [10]. - The top three performing sub-industries were viscose (8.72%), polyester (8.63%), and coatings (6.3%) [11]. Recent Views from the Chemical Team - The tire industry is recovering with increased operating rates and demand, while raw material prices are rising [25]. - The sweetener market, particularly sucralose, is showing signs of improvement with stable pricing and reduced supply [26]. - The dye market remains stable, with steady pricing and normal production levels [27]. - The DMC market is experiencing upward price movement due to improved downstream demand [27]. Key Industry Information - The titanium dioxide market is under pressure due to weak demand and reduced production rates [28]. - The vitamin E market is facing downward price pressure, with significant fluctuations in pricing reported [29]. - The coal chemical sector is stabilizing, with coal prices under pressure but showing signs of bottoming out [38][39].

江苏扬农化工股份有限公司 2024 年年度股东大会会议资料 江苏扬农化工股份有限公司 二〇二四年年度股东大会 会议资料 二〇二五年五月二十六日 江苏扬农化工股份有限公司 2024 年年度股东大会会议资料 二〇二四年年度股东大会议程 ●会议召开的日期、时间： 现场会议召开时间为：2025年5月26日 下午14:00 网络投票起止时间：自2025年5月26日至2025年5月26日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段，即9:15-9:25， 大会召开当日的9:15-15:00 ●现场会议地点：扬州市开发西路203号 扬农大厦5楼会议室 ●主持人：董事长苏赋先生 ●议程： 一、向大会报告议案 二、独立董事作《独立董事 2024 年度述职报告》 三、报告本次股东大会股东及股东代表签到情况 四、审议议案并表决 五、统计表决票 六、宣读本次股东大会决议 七、宣读法律意见书 江苏扬农化工股份有限公司 2024 年年度股东大会会议资料 目 录 江苏扬农化工股份有限公司 2024 年年度股东大会会议资料 江苏扬农化工股份有限公司 一、公司经营管理回顾 （一）2024 年 ...

Group 1 - The company held its 2024 annual performance briefing on May 16, 2025, via an online interactive format [1] - Key executives, including the board secretary and CFO, participated in the briefing and addressed investor inquiries [1] - The company emphasized the significant potential of its innovative herbicides in overseas markets, particularly in rice cultivation areas in Latin America and Southeast Asia, where efficacy assessments have been completed [1][2] Group 2 - The company has two innovative herbicides already on the market, with another undergoing registration review, indicating a strong growth trajectory for innovative herbicide revenue in the coming years [1][2] - The company highlighted the broad application potential of its herbicide, Pyrazosulfuron, in rice fields, which are critical for weed management [1] - The company acknowledged the challenges of industry homogenization and stressed the importance of technological innovation and strategic positioning for future growth [1]

Core Viewpoint - Yabao Chemical (雅本化学) is navigating through a challenging industry cycle but shows signs of recovery with significant revenue growth in Q1 2025 and a substantial reduction in losses, driven by technological innovation and capacity optimization [1][4]. Group 1: Company Performance - In 2024, Yabao Chemical's performance was negatively impacted by industry downturns, market competition, and asset impairment, leading to an overall poor performance [1]. - The company reported a 43.52% year-on-year increase in revenue for Q1 2025, with losses narrowing by over 70%, indicating a recovery signal [1]. - The company’s R&D investment reached 123 million yuan in 2024, accounting for approximately 10% of total revenue [2]. Group 2: Technological Innovation - Yabao Chemical emphasizes the importance of technological innovation as a driving force for the CDMO industry, particularly in areas like continuous manufacturing and biocatalysis [2]. - The company has a total of 237 patents, including 122 invention patents, with a focus on biocatalysis and continuous flow tubular reactions [2]. - The company has successfully published articles in renowned journals, showcasing its research and development capabilities [3]. Group 3: Strategic Focus - The company is committed to a dual development strategy in innovative pesticides and pharmaceuticals, enhancing its integration into global supply chains [3]. - Future plans include optimizing core business areas, accelerating capacity transformation at various bases, and deepening collaborations with major clients [4]. - Yabao Chemical aims to strengthen cost control and supply chain resilience while enhancing sustainable development through ESG initiatives [4].

Core Viewpoint - The company is focusing on the development of new drugs and enhancing its product commercialization process to improve profitability and return value to investors [1][4][5] Group 1: Product Development and Market Strategy - The company is actively developing new drugs, including the integration of seed and pesticide solutions, with ongoing research and development efforts [2][4] - The new product, Pyrazol Quinclorac, is currently in the market promotion phase, indicating a strategic push for new product launches [4][5] - The company has completed the domestic market layout for its new products and is entering a phase of increasing sales volume [5][6] Group 2: Production Capacity and Sales - The monthly production capacity for Acetochlor is approximately 1,000 tons, and the company is currently operating at full capacity due to high demand [3][5] - The company is not planning to expand the production capacity for Acetochlor, focusing instead on new drug development [2][4] - The company anticipates significant profit growth in 2025 due to rising prices of Acetochlor and strong market demand [4][5] Group 3: Market Demand and Pricing - The global demand for Acetochlor is estimated at around 35,000 tons, with expectations for varying growth rates annually [3][4] - The company is experiencing a tight supply situation for Acetochlor, particularly during peak sales seasons [4][5] - The pricing of products is influenced by supply and demand dynamics, with recent price increases expected to enhance profitability [5][6]

Group 1: Financial Performance and Projections - The company experienced a slight decline in revenue in Q1, attributed to delayed purchases and shipments, with expectations for growth in the upcoming half-year report [3][7] - The projected profit growth for 2025 is expected to exceed revenue growth due to strategic planning [7] - The total dividend payout for 2024 is expected to maintain a ratio of over 30% relative to net profit, despite lower overall profits [5] Group 2: Production Capacity and Investment - The company’s original drug production capacity is not meeting expectations primarily due to market changes rather than funding issues [1][2] - The production line for the herbicide Sulfentrazone has been launched, with updates available through company announcements [2] - The company plans to enhance its production capacity in the future, with a focus on strategic investments [9] Group 3: Market Strategy and Management - The company is shifting its management approach from strategic control to operational control for better oversight of global subsidiaries [5][6] - The company aims to improve its gross profit margins by increasing the proportion of higher-margin products and expanding into more profitable markets [9] - The company is committed to maintaining a diverse product portfolio to facilitate one-stop procurement for customers [8] Group 4: Investor Relations and Communication - The company conducts quarterly earnings calls and engages in various investor activities to enhance communication with stakeholders [8] - The company encourages feedback from investors regarding its investor relations activities and is open to suggestions for improvement [8] - The company has launched a WeChat public account to provide timely and accurate information to investors [9]

Group 1: Investment Projects and Financial Impact - The company has several fundraising projects expected to positively impact profits, with projects like the Pyrethroid raw material project and others already reaching production capacity [1] - The two-chlorinated pentachloromethyl pyridine project is completed and expected to start trial production in 2025, contributing to operational performance [1] Group 2: Product Lines and Sales Performance - The company does not produce Acetamiprid-related products but has sales of Cypermethrin-related formulations, with an estimated sales revenue of approximately 11.76 million yuan for 2024 [1] Group 3: Industry Trends and Strategic Positioning - The agricultural pesticide industry is experiencing increased concentration, with top companies accelerating consolidation; the company aims to balance vertical extension and horizontal expansion through resource allocation and potential acquisitions [2] - The company plans to enhance its core business through mergers and acquisitions to expand market share and strengthen competitiveness [2] Group 4: Environmental Responsibility and Sustainability - The company has reported a 2.1% year-on-year reduction in carbon emissions per unit of output, which is below the industry average; it is committed to improving green production capabilities in line with carbon neutrality goals [2] - The company emphasizes sustainable development and environmental protection, integrating energy-saving and emission-reduction initiatives across various operational stages [2]

Core Viewpoint - The recent approval of the new herbicide Temper™ More by Adama Agricultural Solutions in the United States represents a significant advancement in managing herbicide-resistant weeds, providing farmers with an effective tool to combat persistent weed resistance [1][3]. Group 1: Product Features - Temper™ More utilizes Adama's proprietary Sesgama® formulation technology, enhancing the stability and ease of application of the active ingredients, isoxaflutole and glyphosate [4]. - The product combines two active ingredients with different modes of action, offering a broad spectrum of efficacy against glyphosate-resistant weeds, including pigweed, morning glory, and waterhemp [3][4]. - The dual-action mechanism of Temper™ More allows for prolonged effectiveness, optimizing weed management and reducing the frequency of applications, which can save farmers time and money [3][4]. Group 2: Market Impact - The introduction of Temper™ More addresses the growing challenge of herbicide resistance faced by farmers across the U.S., where traditional glyphosate applications are becoming less effective [2][3]. - The product's flexibility in application timing provides farmers with greater freedom in managing their crop protection strategies, alleviating mid-season application pressures [3][4]. - Adama has conducted extensive trials in key regions, demonstrating that Temper™ More consistently outperforms glyphosate and other single-agent herbicides, particularly against the most widespread and difficult-to-control resistant waterhemp [4].